2024 News Release 2023 News Release 2022 News Release 2021 News Release 2020 News Release 2019 News Release 2025 News Release Filters 2024 News Release 2023 News Release 2022 News Release 2021 News Release 2020 News Release 2019 News Release 2025 News Release Date Name Desc Asc Clear Filters 2024 News Release December 23, 2024 Gain Therapeutics Initiates Phase 1b Clinical Trial of Lead Candidate GT-02287 in People with GBA1 and Idiopathic Parkinson’s Disease Read More December 11, 2024 Gain Therapeutics To Present At Biotech Showcase 2025 Read More November 14, 2024 Gain Therapeutics Reports Financial Results for Third Quarter 2024 and Provides Corporate Update Read More October 23, 2024 Gain Therapeutics Presents Data at 36ᵗʰ EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics Demonstrating Identification of Allosteric Inhibitors Targeting DDR2 Read More October 15, 2024 Gain Therapeutics Announces Poster Presentation at 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics Read More October 9, 2024 Gain Therapeutics to Present at Michael J. Fox Foundation’s 16th Annual Parkinson’s Disease Therapeutics Conference Read More October 7, 2024 Gain Therapeutics Presents Preclinical GT-02287 Data at Neuroscience 2024 Read More October 3, 2024 Gain Therapeutics to Participate at Upcoming Investor Conferences Read More September 30, 2024 Gain Therapeutics Presents Phase 1 GT-02287 Data at International Congress of Parkinson’s Disease and Movement Disorders Demonstrating Increase in GCase Activity in Healthy Volunteers Read More September 26, 2024 Gain Therapeutics To Host Virtual Webinar on Results From Phase 1 Study and Design of Upcoming Phase 1b Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for Parkinson’s Disease Read More
